Evidence map›Paper›PMID 19342682›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2009

The pattern recognition receptor CD36 is a chondrocyte hypertrophy marker associated with suppression of catabolic responses and promotion of repair responses to inflammatory stimuli.

Denise L Cecil, C Thomas G Appleton, Monika D Polewski, John S Mort, Ann Marie Schmidt, Alison Bendele, Frank Beier, Robert Terkeltaub

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 59 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. The Calcium Binding Protein S100A11 and Its Roles in Diseases.Frontiers in cell and developmental biology · 2021
    Review
  11. Review
  12. Article
  13. Osteogenic Potential of Caspases Related to Endochondral Ossification.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2018
    Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 2 countries.

Denise L CecilDepartment of Medicine, Rheumatology Section, Veterans Affairs Health Care System/University of California, San Diego, CA 92161, USA.
C Thomas G Appleton
Monika D Polewski
John S Mort
Ann Marie Schmidt
Alison Bendele
Frank Beier
Robert Terkeltaub
Western University · CAColumbia University · USShriners Hospitals for Children - Canada · CAUniversity of California, San Diego · USUniversity of Colorado Boulder · USVA Northern California Health Care System · USVA San Diego Healthcare System · US

Funding

NPP1 and Molecular Mechanisms in Artery CalcificationR01HL077360 · NHLBI · VETERANS MEDICAL RESEARCH FDN/SAN DIEGO · PI TERKELTAUB, ROBERT A. · 2004 to 2012
$2.2M
Chondrocyte S100/Calgranulins and RAGE in OsteoarthritisR01AR054135 · NIAMS · VETERANS MEDICAL RESEARCH FDN/SAN DIEGO · PI TERKELTAUB, ROBERT A. · 2006 to 2009
$945k
SPEECH UNDERSTANDING UNDER NONOPTIMAL CONDITIONS IN AGINR01AG007998 · NIA · U.S. DEPT/VETS AFFAIRS MED CTR(MARTINEZ) · PI DIVENYI, PIERRE L · 1989 to 2003
$688k
NHLBI NIH HHS HL077360NHLBI NIH HHS R01 HL077360NIAMS NIH HHS AR54135NIAMS NIH HHS R01 AR054135NIA NIH HHS R01 AG007998PHS HHS PAG07998
6 · The paper itself

Abstract

Multiple inflammatory mediators in osteoarthritis (OA) cartilage, including S100/calgranulin ligands of receptor for advanced glycation end products (RAGE), promote chondrocyte hypertrophy, a differentiation state associated with matrix catabolism. In this study, we observed that RAGE knockout was not chondroprotective in instability-induced knee OA in 8-wk-old mice. Hence, we tested the hypothesis that expression of the alternative S100/calgranulin and patterning receptor CD36, identified here as a marker of growth plate chondrocyte hypertrophy, mediates chondrocyte inflammatory and differentiation responses that promote OA. In rat knee joint destabilization-induced OA, RAGE expression was initially sparse throughout cartilage but increased diffusely by 4 wk after surgery. In contrast, CD36 expression focally increased at sites of cartilage injury and colocalized with developing chondrocyte hypertrophy and aggrecan cleavage NITEGE neoepitope formation. However, CD36 transfection in normal human knee-immortalized chondrocytes (CH-8 cells) was associated with decreased capacity of S100A11 and TNF-alpha to induce chondrocyte hypertrophy and ADAMTS-4 and matrix metalloproteinase 13 expression. S100A11 lost the capacity to inhibit proteoglycans synthesis and gained the capacity to induce proteoglycan synthesis in CD36-transfected CH-8 cells. Moreover, S100A11 required the p38 MAPK pathway kinase MKK3 to induce NITEGE development in mouse articular cartilage explants. However, CH-8 cells transfected with CD36 demonstrated decreased S100A11-induced MKK3 and p38 phosphorylation. Therefore, RAGE and CD36 patterning receptor expression were linked with opposing effects on inflammatory, procatabolic responses to S100A11 and TNF-alpha in chondrocytes.

Indexed as

AnimalsBiomarkersCD36 AntigensCell DifferentiationCell LineChondrocytesDisease Models, AnimalHumansHypertrophyInflammationMaleMAP Kinase Kinase 3MiceMice, KnockoutOsteoarthritis, Kneep38 Mitogen-Activated Protein KinasesBiomarkersCD36 AntigensMAP Kinase Kinase 3p38 Mitogen-Activated Protein KinasesReceptor for Advanced Glycation End ProductsReceptors, ImmunologicS100A11 protein, humanS100 Proteins

Identifiers

PMID19342682
PMCPMC2698125
OpenAlexW1514071530

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.